Interobserver and intraobserver variability of fetal and maternal Doppler measurements: systematic review and meta-analysis.

Ultrasound Obstet GynecolAug 8, 2026 (epub)
Clinical ResearchObstetrics & GynecologyOpen access

L I Prins, N El Guili, C A Naaktgeboren et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the variability of Doppler ultrasound measurements of umbilical artery (UA), fetal middle cerebral artery (MCA), and uterine artery (UtA) in pregnancy. The analysis included 26 studies with 2457 patients. The pooled intraobserver ICC for UA pulsatility index was 0.88, while the interobserver ICC was 0.68, indicating variability in measurements.

Key findings

  • Pooled intraobserver ICC for UA pulsatility index was 0.88 (95% CI, 0.77-0.94).
  • Pooled interobserver ICC for UA pulsatility index was 0.68 (95% CI, 0.55-0.79).
  • Pooled intraobserver ICC for MCA pulsatility index was 0.85 (95% CI, 0.69-0.93).
  • Mean UtA pulsatility index had a pooled intraobserver ICC of 0.90 (95% CI, 0.85-0.93).

Why it matters

Understanding the variability in Doppler ultrasound measurements is crucial for clinicians as it impacts the reliability of fetal assessments. Improved reproducibility can enhance clinical decision-making and patient outcomes in obstetric care.

Source

PubMed · PMID 42570334Free full text on PubMed Central

Published in Ultrasound Obstet Gynecol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Obstetrics & Gynecology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.